Insider Selling: Personalis (NASDAQ:PSNL) CEO Sells 80,091 Shares of Stock

Personalis, Inc. (NASDAQ:PSNL) CEO Christopher Hall sold 80,091 shares of the business’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $11.02, for a total transaction of $882,602.82. Following the transaction, the chief executive officer owned 235,986 shares in the company, valued at approximately $2,600,565.72. This trade represents a 25.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Personalis Stock Performance

PSNL traded up $0.42 during midday trading on Friday, reaching $11.40. The company had a trading volume of 4,471,474 shares, compared to its average volume of 2,505,722. The business has a 50-day moving average price of $6.86 and a two-hundred day moving average price of $8.10. The stock has a market cap of $1.19 billion, a PE ratio of -11.18 and a beta of 1.96. Personalis, Inc. has a 12-month low of $3.84 and a 12-month high of $11.85.

Personalis (NASDAQ:PSNL) last posted its earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). The firm had revenue of $15.47 million for the quarter, compared to the consensus estimate of $14.49 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. On average, research analysts anticipate that Personalis, Inc. will post -1.06 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in PSNL. Royal Bank of Canada raised its holdings in Personalis by 3.2% in the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after purchasing an additional 2,395 shares in the last quarter. Dynamic Technology Lab Private Ltd raised its holdings in Personalis by 75.6% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company’s stock worth $269,000 after purchasing an additional 33,044 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Personalis by 55.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company’s stock worth $998,000 after purchasing an additional 101,706 shares in the last quarter. Focus Partners Wealth bought a new position in Personalis in the 1st quarter worth $47,000. Finally, JPMorgan Chase & Co. raised its holdings in Personalis by 505.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 29,491 shares of the company’s stock worth $193,000 after purchasing an additional 24,621 shares in the last quarter. 61.91% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen cut shares of Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Morgan Stanley cut their price objective on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. BTIG Research cut their price objective on shares of Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Monday, May 11th. Needham & Company LLC upped their price objective on shares of Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research note on Tuesday, April 21st. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $11.00.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.